Page 206 - DUOKOPT BIBLIOBOOK

DUOKOPT - bibliography book - CONFIDENTIAL - document for exclusive use by personnel of Laboratoires Théa – DO NOT DISTRIBUTE
®

a: statistically significant
difference compared to
baseline
b: clinically significant
difference from baseline
(difference > 7)

Figure 12: GSS change

CONCLUSIONS: Switching from preserved therapies to preservative free DTFC significantly increases pa-
tient’s quality of life (QoL). Removing preservatives from treatment regimens has been suggested to signifi-
cantly and rapidly decrease ocular symptoms and medication-related adverse reactions.

KEY MESSAGES

X PF significantly increases in the patients’ perceptions of their ocular-related QoL impro-
vement after the switch to DTFC UD treatment.

STRENGTHS

X 8 week prospective study (80 patients) after the switch from preserved to preservative
free FTDC.

X The results on the favorable tolerability profile of TDFC UD therapy support this preser-
vative-free combanation therapy to be a valid option when considering additional
treatment options in patient whose target IOP has not be achieved under monotherapy.

WEAKNESSES

X The non-interventional study imposes that the specific ocular surface testing was not
possible.

MARKETING CLAIM

X Switching from preserved to preservative-free Dorzolamide-Timolol combination
improves ocular surface symptoms and patients vision related to quality of life.

206